Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmacology

Background:

• Peptide receptor radionuclide therapy (PRRT) is gaining importance for treating inoperable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
• Commonly used radiopeptides like 90Y-DOTATOC and 177Lu-DOTATATE demonstrate comparable efficacy in tumor response rates.
• The therapy is generally well-tolerated with minimal side effects.

Purpose of the Study:

• To review the current role and potential improvements of PRRT in managing GEP-NETs.
• To highlight the safety profile and therapeutic applications of PRRT.
• To assess the feasibility of PRRT as a first-line treatment for advanced GEP-NETs.

Main Methods:

• Review of current literature on PRRT for GEP-NETs.
• Analysis of efficacy and safety data for 90Y-DOTATOC and 177Lu-DOTATATE.
• Exploration of potential combination therapies and novel administration strategies.

Main Results:

• PRRT with 90Y-DOTATOC and 177Lu-DOTATATE shows tumor response rates of 15-35%.
• Kidney protection with amino acids is recommended, particularly during 90Y-DOTATOC infusion.
• Potential improvements include combining PRRT with radiosensitizers or exploring alternative administration routes.

Conclusions:

• PRRT is a safe and effective treatment option for GEP-NETs.
• Further research into combination therapies and expanded applications could enhance PRRT's role.
• With wider adoption, PRRT could become a standard first-line therapy for advanced GEP-NETs.